iSBTc 25th Annual Meeting
Annual Meeting Main Page | Annual Meeting Highlights | Program Purpose | Presentation Slides & Schedule
Faculty | Abstracts | Hot Topic Symposium | Hot Topic Highlights | Award Recipients
Early Career Scientists | Session Goals | Final Program | Photos | Meeting Summary
October 2 - 4, 2010
Hyatt Regency Washington on Capitol Hill
Washington, D.C.
Session Goals
The following details the goals of each Annual Meeting education session.
Adoptive T Cell Transfer: The Next Wave
(Session Date: Monday, October 4)
- Provide an update on progress T cell therapy for cancer, and discuss rational combinations with other immune modulatory agents.
Clinical Trial Endpoints
(Session Date: Saturday, October 2)
- Address clinical trial design from the standpoint of testing biologic therapies for cancer, with a particular focus on clinical trial endpoints that may be most appropriate for evaluating biologic therapies.
Countering Negative Regulation
(Session Date: Sunday, October 3)
- Discuss the most up-to-date information on negative regulatory mechanisms in the tumor microenvironment, and highlight their translation to preclinical models and clinical application.
Dendritic Cells and Cancer
(Session Date: Saturday, October 2)
- Discuss recent progress in clinical evaluation of dendritic cell vaccines against established cancer and the latest developments related to improvement of DC-based therapies.
Immune Cell Trafficking to Tumor Microenvironment
(Session Date: Sunday, October 3)
- While vaccination and adoptive T cell therapy can increase the frequency of circulating tumor antigen-specific T cells, in order for those cells to reject tumors they need to traffic to the tumor microenvironment. This session will discuss the current knowledge of regulation of T cell trafficking into tumor sites and introduce strategies to facilitate T cell recruitment as a therapeutic approach.
Innate / Adaptive Immune Interplay in Cancer
(Session Date: Saturday, October 2)
- Discuss regulation of innate effector functions during cancer-induced inflammation or therapy of cancer.
Targeted Therapeutics and Immunotherapy
(Session Date: Saturday, October 2)
- Review specific immunologic targets that have been the focus of therapeutic development.
- Discuss overcoming resistance to targeted therapies in cancer.
Vaccine Combinations
(Session Date: Sunday, October 3)
- Identify promising combinations of agents to augment clinical activity.
